ViroLogic

ViroLogic, a privately held South San Francisco-based biotechnology company, is a leader in the development of novel therapy guidance tools to enable patients, physicians, and medical reimbursers to make rational treatment decisions in the management of viral diseases. The company's proprietary technology is also being used in the fields of viral pharmacogenomics to identify, analyze, and select new drug candidates for treating viral diseases and cancer, and in disease management through the development of therapy guidance algorithms to guide patient therapy. ViroLogic sales representatives have been in the field since November 1999 raising awareness among HIV-treating physicians of phenotypic testing and its benefits.

Contact Details: 270 East Grand Avenue South San Francisco CA 94080 United States of America Tel: Fax: Email: WWW: www.virologic.com/

Loading...

Recent Publications by ViroLogic:
Assessing chemokine co-receptor usage in HIV. PURPOSE OF REVIEW: HIV entry into cells is mediated through sequential...	30th April, 2005	ViroLogic Inc, South San Francisco, California 94080, USA.	Curr Opin Infect Dis. 2005 Feb;18(1):9-15.
Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Wild-type viruses from the ViroLogic phenotype-genotype database were...	12th March, 2004	ViroLogic, Inc., South San Francisco, California 94080, USA.	Antimicrob Agents Chemother. 2004 Feb;48(2):437-43.
Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility. Maturation of infectious human immunodeficiency virus type 1 (HIV-1)...	12th December, 2003	ViroLogic, South San Francisco, California 94080, USA.	AIDS Res Hum Retroviruses. 2003 Sep;19(9):779-84. DOI Direct Link
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. Nucleoside reverse-transcriptase inhibitors (NRTIs) are important...	5th November, 2003	ViroLogic, South San Francisco, California 94080, USA.	J Infect Dis. 2003 Oct 1;188(7):992-1000. Epub 2003 Sep 16. DOI Direct Link
Practical applications of viral fitness in clinical practice. PURPOSE OF REVIEW: To review recent clinical data regarding viral fitness...	12th August, 2003	Division of Clinical Research, ViroLogic, Inc., San Francisco, CA 94080,	Curr Opin Infect Dis. 2003 Feb;16(1):11-8. DOI Direct Link
→View more ViroLogic research publications.

Press Releases on ViroLogic:
PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer	29th April, 2009	PDL BioPharma, Inc.	- Company Updates Board of Directors Audit Committee Members and Complies with Nasdaq Rule - INCLINE VILLAGE, Nev., April 29 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today
Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017	14th April, 2009	Washington G-2 Reports	Washington G-2 Reports releases 2009 Laboratory market projections. NEWARK, N.J., April 14 /PRNewswire/ -- A new study from market research firm Washington G-2 Reports indicates that the clinical

BioNews Results for ViroLogic:
Father of sick boy develops oseltamivir-resistant H1N1	New England Journal of Medicine:  Nov 12 2009 2:26AM Matching: virologic
Nov 11 N Engl J Med letter	New England Journal of Medicine:  Nov 12 2009 2:26AM Matching: virologic
INCIDENCE OF VIROLOGIC ESCAPE OBSERVED DURING ITMN-191 (R7227) MONOTHERAPY IS GENOTYPE DEPENDENT, ASSOCIATED W	National AIDS Treatment Advocacy Project:  Nov 10 2009 3:31AM Matching: virologic
Kinetic Analysis Of Viral Rebound And Drug-resistant Viral Variant Dynamics In Patients Treated With Itmn-191	National AIDS Treatment Advocacy Project:  Nov 10 2009 3:31AM Matching: virologic
Telaprevir, Peginterferon Alfa-2a and Ribavirin Improved Rates of Sustained Virologic Response (SVR) in 'Diffi	National AIDS Treatment Advocacy Project:  Nov 10 2009 3:31AM Matching: virologic
Promote your company here: BioNewsCast - Press Release Distribution	→View more ViroLogic news.

ViroLogic Clinical Trials:
TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)

ViroLogic Patents:
US Patent No.	Title
7037644	Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
6942969	Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
6869759	Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
6653081	Methods for monitoring antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS
6489098	Means and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
→View more ViroLogic patents.

ViroLogic (VLGC) Financial information Links from Barchart
VLGC Quote from from Barchart.com
VLGC Chart from from Barchart.com
VLGC Profile from from Barchart.com
VLGC Opinion from from Barchart.com
→View more ViroLogic finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 491 times since April 2007, the link to the organisation's website has been followed 111 times

Recent Search Terms used to find this page: virologic logo | virologic | ViroLogic Inc. South San Francisco CA USA | ViroLogic Inc. South San Francisco CA USA | Virologic ca | Virologic ca | virologic south san-francisco ca | Virologic | virologic inc | virologic careers | .

Search for more companies in South San Francisco

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for ViroLogic